Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

ACADIA PHARMACEUTICALS INC

ACAD · Nasdaq · CIK 0001070494 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

21 Form 4 transaction lines observed in the same window
9 sales · 12 option, withholding, award, gift or other lines

Last qualifying purchase2023-05-24 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $14.1M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
○▼○▼○▼
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
○▼▼▼
Thompson Elizabeth H.Z.EVP, Head of Research & Dev
○▼
667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPDirector,TenPercentOwner
○
Poole JonathanDirector
○
Ndu AdoraDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-05-24 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.

Recent Form 4 activity

0Purchases
24Sales
24Other Form 4 lines
24SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING9 sale line(s) · context only
OTHER12 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-31.0%
3M
-22.6%
6M
-10.1%
12M
—

Volatility & liquidity

Volatility
39.2%
Beta
0.86
Avg daily value
USD 36.1M

Valuation

Market cap
USD 3.4B
P/E
8.9×

Fundamentals

Profit margin
36.5%
ROE
31.9%
Industry
Biotechnology

Market data

Price data up to: 2026-10-04 · Price source: OpenBB/yfinance · From SEC filings: Profit margin, ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap, P/E · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
8,275,918
Previous report
9,666,972
Avg daily volume
2,828,484
Days to cover
2.9

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-05-24667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock553,263USD 25.48USD 14,096,156SEC filing ↗
2023-05-23667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock209,053USD 25.41USD 5,312,432SEC filing ↗
2023-05-22667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock134,206USD 24.57USD 3,297,779SEC filing ↗
2020-03-18667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock135,897USD 33.52USD 4,555,330SEC filing ↗
2020-03-17667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock219,800USD 32.84USD 7,218,880SEC filing ↗
2020-03-16667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock694,303USD 31.51USD 21,875,568SEC filing ↗

Form 4 evidence

48 transaction lines in the latest 365-day window; 405 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-06Schneyer Mark C.Sale (S)Common Stock14,292USD 29.22USD 417,627SEC filing ↗
2026-08-06Schneyer Mark C.Option exercise / conversion (M)Common Stock14,292USD 17.84USD 254,969SEC filing ↗
2026-08-05Schneyer Mark C.Sale (S)Common Stock5,849USD 29.00USD 169,621SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-06Schneyer Mark C.Sale (S)Common Stock14,292USD 29.22USD 417,627SEC filing ↗
2026-08-06Schneyer Mark C.Option exercise / conversion (M)Common Stock14,292USD 17.84USD 254,969SEC filing ↗
2026-08-05Schneyer Mark C.Sale (S)Common Stock5,849USD 29.00USD 169,621SEC filing ↗
2026-08-05Schneyer Mark C.Option exercise / conversion (M)Common Stock5,849USD 17.84USD 104,346SEC filing ↗
2026-07-30Thompson Elizabeth H.Z.Sale (S)Common Stock16,558USD 26.13USD 432,663SEC filing ↗
2026-07-29Thompson Elizabeth H.Z.Option exercise / conversion (M)Common Stock32,272USD —USD —SEC filing ↗
2026-06-26Kihara JamesSale (S)Common Stock11,421USD 26.08USD 297,860SEC filing ↗
2026-05-29667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPAward / grant (A)Common Stock18,622USD 0.00USD 0SEC filing ↗
2026-05-29Poole JonathanOption exercise / conversion (M)Common Stock2,010USD —USD —SEC filing ↗
2026-05-29Ndu AdoraOption exercise / conversion (M)Common Stock8,107USD —USD —SEC filing ↗
2026-05-29HARRIGAN EDMUNDOption exercise / conversion (M)Common Stock8,107USD —USD —SEC filing ↗
2026-05-29GAROFALO ELIZABETH A.Option exercise / conversion (M)Common Stock8,107USD —USD —SEC filing ↗
2026-05-29Daly James MOption exercise / conversion (M)Common Stock8,107USD —USD —SEC filing ↗
2026-05-29Brege LauraOption exercise / conversion (M)Common Stock8,107USD —USD —SEC filing ↗
2026-05-26Kihara JamesSale (S)Common Stock5,401USD 21.18USD 114,393SEC filing ↗
2026-05-04Schneyer Mark C.Sale (S)Common Stock3,506USD 21.79USD 76,396SEC filing ↗
2026-05-04Kihara JamesSale (S)Common Stock1,332USD 21.79USD 29,024SEC filing ↗
2026-05-01Schneyer Mark C.Option exercise / conversion (M)Common Stock6,815USD —USD —SEC filing ↗
2026-05-01Kihara JamesOption exercise / conversion (M)Common Stock2,596USD —USD —SEC filing ↗
2026-04-07Schneyer Mark C.Sale (S)Common Stock2,709USD 22.20USD 60,140SEC filing ↗
2026-04-07Kihara JamesSale (S)Common Stock1,030USD 22.20USD 22,866SEC filing ↗
2026-04-05Schneyer Mark C.Option exercise / conversion (M)Common Stock5,276USD —USD —SEC filing ↗
2026-04-05Kihara JamesOption exercise / conversion (M)Common Stock2,010USD —USD —SEC filing ↗
2026-03-26Schneyer Mark C.Sale (S)Common Stock3,208USD 21.65USD 69,456SEC filing ↗
2026-03-26Kihara JamesSale (S)Common Stock1,109USD 21.65USD 24,011SEC filing ↗
2026-03-25Thompson Elizabeth H.Z.Sale (S)Common Stock3,435USD 21.47USD 73,749SEC filing ↗
2026-03-25Schneyer Mark C.Sale (S)Common Stock4,177USD 21.47USD 89,680SEC filing ↗
2026-03-25Schneyer Mark C.Option exercise / conversion (M)Common Stock6,178USD —USD —SEC filing ↗
2026-03-25Rhodes Jennifer JSale (S)Common Stock3,844USD 21.47USD 82,531SEC filing ↗
2026-03-25Owen Adams CatherineSale (S)Common Stock11,641USD 21.47USD 249,932SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerACAD
CIK0001070494
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history405 transaction lines from 2020-01-07 to 2026-08-06
40 P purchase lines · 167 S sale lines · 198 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.